drugset / Trial / NCT00162799
Efficacy Pilot Study of Triflusal in the Attenuation of Insulin Resistance in Human Obesity
RandomizedCrossoverDouble-blindTreatment
Summary
To explore the efficacy of triflusal in the attenuation of insulin resistance in human obesity. Triflusal is a salicylate compound approved in several countries as antithrombotic agent (antiplatelet). The hypothesis is to explore if there is a reduction of obesity-induced insulin resistance by triflusal.
Timeline
- Start
- 2002-07
- Primary completion
- —
- Completion
- 2004-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Triflusal | Small molecule | 600 mg | — |
| Subject | Triflusal | Small molecule | 900 mg | — |
Indications
No indication recorded.